AXL and acute myeloid leukemia: As previously noted, in a FLT3-ITD AML cell line resistant to FLT3 inhibition, treatment with TP-0903 resensitized the cells to two different FLT3 small molecule inhibitors [81], implicating dual inhibition of FLT3 and AXL as an intriguing therapeutic strategy in AML.